Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapy

27 Sept 2024

Abstract excerpt

BACKGROUND: Chimeric antigen receptor (CAR)-T therapy has emerged as a promising treatment for hematologic malignancies. However, cytopenia remains one of the most frequent and challenging adverse effects of this therapy. METHODS: We conducted a retrospective analysis of 26 patients with relapsed/refractory aggressive B-cell lymphoma who received CAR-T therapy at our center. Subsequently, to investigate measures...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cutaneous lymphoproliferative disorders research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39334276
DOI: 10.1186/s13287-024-03941-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapyPMID 39334276Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factorsSemantic proximity Read ↗

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple MyelomaSemantic proximity Read ↗

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read ↗

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Semantic proximity Read ↗

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cellsSemantic proximity Read ↗

CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read ↗

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisSemantic proximity Read ↗

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.